Abstract
Volatile anesthetics have pharmacokinetic and pharmacodynamic properties that are ideally suited to the cardiac surgical ICU. Since the development of the Anesthetic Conserving Device (AnaCONDaTM, Sedana Medical, Uppsala, Sweden), their use in this setting has increased. Randomized trials have shown it to be associated with shorter time to extubation and, in the cardiac surgery population, lower postoperative biomarker peak, suggesting a potential therapeutic benefit. Existing studies have been underpowered to show an impact on ICU or hospital length-of-stay (LOS), major adverse cardiovascular events (MACE) or mortality. As such, we undertook a systematic review and meta-analysis, emphasizing their efficacy and safety in the context of a fast-track approach to postoperative care.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
